Lv12
38 积分 2025-03-24 加入
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy
6小时前
已完结
Caractéristiques des cancers bronchiques non à petites cellules EGFR positifs avec mutation de résistance L718Q ou G724S sous osimertinib. EXPLORE L718Q GFPC
17小时前
已完结
Rare case of de novo EGFR L718V mutation-positive non-small cell lung cancer successfully treated with afatinib
17小时前
已完结
Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation
20小时前
已完结
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
15天前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
19天前
已完结
Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside
1个月前
已完结
TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression
1个月前
已完结
皖公网安备34019202002308
